08.07.2019 • NewsElaine BurridgeHexion

Hexion Emerges from Chapter 11

President and CEO Craig Rogerson said Hexion will accelerate new product...
President and CEO Craig Rogerson said Hexion will accelerate new product development

Hexion has emerged from Chapter 11 bankruptcy protection as of Jul. 1 following confirmation of its financial reorganization plan by the US Bankruptcy Court for the District of Delaware on Jun. 24.

The company announced it had reduced its debt of more than $2 billion, received an infusion of $300 million in equity capital through a rights offering and raised approximately $2 billion in exit financing.

The Columbus, Ohio-based resins producer filed for bankruptcy protection on Apr. 1, 2019, as part of a plan to reduce its $3.9 billion net debt burden. The filing included all Hexion’s US subsidiaries and a non-operating entity in Nova Scotia, Canada.

Hexion said that with a strengthened capital structure and substantial free cash flow after debt service, it is now “well-positioned to make substantial reinvestments into its businesses to fuel strategic growth and drive value for its stakeholders”.

President and CEO Craig Rogerson said Hexion will accelerate new product development. He commented: “Our growth strategy will be driven by investments in innovative products using our research and development capabilities and strategic partnerships, capitalizing on our global manufacturing footprint and commitment to sustainability. Going forward, we are well-positioned to take advantage of our operational momentum.”

Hexion regards itself as the global leader in forest products and epoxy, phenolic and coatings resins, holding the number one or two market positions.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.